Fluticasone Furoate Inhalation Powder

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Asthma

Phase 3

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

CompletedNCT01134042

GlaxoSmithKlineAsthma

Start: 2010-06-30End: 2011-10-31Updated: 2017-01-11

Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

CompletedNCT01165138

GlaxoSmithKlineAsthma

Start: 2010-08-20End: 2011-10-19Updated: 2018-02-14

A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma

CompletedNCT01244984

GlaxoSmithKlineAsthma

Start: 2010-07-31End: 2012-01-31Updated: 2017-01-11

Related Papers

Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma

Respiratory Research2016-11-2311 citations

An Integrated Analysis of Fluticasone Furoate/Vilanterol (FF/VI) Versus FF Safety Data Across Phase II and III Asthma Studies

Pulmonary Therapy2016-05-121 citations

Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials.

2015-12-246 citations

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study

PLoS ONE2015-04-2088 citations